PriceP. B.TaylorC. W. and NelsonD. E.Measurement and Predictors of Physician Performance: Two Decades of Intermittently Sustained Research (Salt Lake City: Aaron Press, 1971): 121–149.
2.
SadeR. M.StroudM. R.LevineJ. H. and FlemingG. A., “Criteria for Selection of Future Physicians,”Annals of Surgery201, no. 2 (1985): 225–230.
3.
Council on Ethical and Judicial Affairs of the American Medical Association, “Gifts to Physicians from Industry,”JAMA265, no. 4 (1991): 501.
4.
OlivieriN. F.BrittenhamG. M.McLarenC. E.TempletonD. M.CameronR.G.McClellandR. A.BurtA. D. K. A. and FlemingK. A., “Long-term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major,”New England Journal of Medicine339, no. 7 (1998): 417–423.
5.
KondroW., “Canadian Panel Calls for Review of Drug-trial Confidentiality Agreements,”The Lancet352, no. 9145 (1998): 1996.
6.
ShuchmanM., “Independent Review Adds to Controversy at Sick Kids,”Canadian Medical Association Journal160, no. 3 (1999): 386–368.
7.
StelfoxH. T.ChuaG.O'RourkeK. and DetskyA. S., “Conflict of Interest in the Debate over Calcium-Channel Antagonists,”New England Journal of Medicine338, no. 23 (1998): 101–106.
8.
BodenheimerT., “Uneasy Alliance – Clinical Investigators and the Pharmaceutical Industry,”New England Journal of Medicine342, no. 20 (2000): 1539–1544.
9.
AngellM., “Is Academic Medicine for Sale?”New England Journal of Medicine342, no. 20 (2000): 1516–1518.
10.
WazanaA., “Physicians and the Pharmaceutical Industry: Is a Gift Ever just a Gift?”JAMA283, no. 20 (2000): 373–380.
11.
StosselT. P., “Regulating Academic-Industrial Research Relationships – Solving Problems or Stifling Progress?”New England Journal of Medicine353, no. 10 (2005): 1060–1065.
12.
BrennanT. A.RothmanD. J.BlankL.BlumenthalD.ChimonasS. C.CohenJ. J.GoldmanJ.KassirerJ. P.KimballH.NaughtonJ. and SmelserN., “Health Industry Practices that Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers,”JAMA295, no. 4 (2006): 429–433.
